1000例胃肠间质瘤手术患者:伊马替尼前后时代的结局分析
该单中心回顾性研究分析了1982至2016年间接受手术的1000例胃肠间质瘤(GIST)患者,按初发、初发伴转移、异时复发转移分层,比较伊马替尼时代前后的总生存(OS)与无复发生存(RFS)。结果显示伊马替尼时代各分层OS均延长;在伊马替尼时代,仅肿瘤大小>10cm仍为RFS和OS的独立预后因素。
要点
- 伊马替尼时代各表现分层的GIST手术患者OS均较前延长。
- 伊马替尼时代仅肿瘤大小>10cm仍独立预测RFS和OS。
- 高危特征患者仍应接受伊马替尼治疗。
核心结论
- 伊马替尼时代接受手术的GIST患者在所有表现分层中总生存均延长。
- 在伊马替尼时代,肿瘤部位、大小和核分裂率中仅大小>10cm与结局独立相关。
- 具有高危特征的患者仍应接受伊马替尼治疗。
研究设计与样本
- 单中心回顾性分析1982至2016年接受手术的1000例GIST患者。
- 按表现状态分为仅原发肿瘤(PRIM)、原发伴同时性转移(PRIM+MET)、异时复发/转移(MET),并按伊马替尼时代分层。
- 采用Cox比例风险模型和Kaplan-Meier法估计总生存(OS)和无复发生存(RFS)。
主要发现
- 伊马替尼时代各表现分层的OS均长于前伊马替尼时代,包括Miettinen高危原发肿瘤。
- 前伊马替尼时代PRIM患者的多因素分析中,肿瘤部位、大小和核分裂率与OS和RFS独立相关。
- 伊马替尼时代接受伊马替尼(新辅助和/或辅助)的PRIM患者风险更高,但调整治疗后可独立预测RFS和OS的仅肿瘤大小>10cm(RFS HR 3.85,95%CI 2.00-7.40,P<0.0001;OS HR 3.37,95%CI 1.60-7.13,P=0.001)。
临床怎么用
- 对于GIST手术患者,应结合伊马替尼治疗时代背景评估预后。
- 肿瘤大小>10cm可作为伊马替尼时代独立的预后风险指标。
- 高危特征患者仍应接受伊马替尼治疗。
局限性
- 本研究为单中心回顾性分析,可能存在选择偏倚。
- 研究跨越1982至2016年,治疗和诊断方法随时间变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the results of surgery for gastrointestinal stromal tumor (GIST) in the pre and post-imatinib eras at a single institution and to identify current prognostic clinicopathologic factors. BACKGROUND: Imatinib has radically changed the management of GIST, yet the magnitude of impact on outcome across the spectrum of GIST presentation and relevance of historical prognostic factors are not well defined. METHODS: We retrospectively analyzed 1000 patients who underwent surgery for GIST at our institution from 1982 to 2016. Patients were stratified by presentation status as primary tumor only (PRIM), primary with synchronous metastasis (PRIM + MET), or metachronous recurrence/metastases (MET), and also imatinib era (before and after it became available). Cox proportional-hazard models and Kaplan-Meier methods were used to model and estimate overall survival (OS) and recurrence-free survival (RFS). RESULTS: OS was longer in the imatinib era compared with the pre-imatinib era in each presentation group, including in Miettinen high-risk primary tumors. Among PRIM patients from the pre-imatinib era, tumor site, size, and mitotic rate were independently associated with OS and RFS on multivariate analysis. PRIM patients in the imatinib era who received imatinib (neoadjuvant and/or adjuvant) had higher risk tumors, but after adjusting for treatment, only size >10 cm remained independently prognostic of RFS [hazard ratio (HR) 3.85, 95% confidence interval (CI) 2.00-7.40, P < 0.0001) and OS (HR 3.37, 95% CI 1.60-7.13, P = 0.001)]. CONCLUSIONS: Patients treated in the imatinib era had prolonged OS across all presentations. In the imatinib era, among site, size, and mitotic rate, high-risk features were associated with treatment with the drug, but only size >10 cm correlated with outcome. Imatinib should still be prescribed for patients with high-risk features.
引用
- Cavnar MJ, Seier K, Curtin C, et al. Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras. Ann Surg. 2021. PMID: 30946076. doi:10.1097/SLA.0000000000003277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。